Objective: Despite long-standing safe and effective use of immunoglobulin replacement therapy (IgRT) in primary immunodeficiency, clinical data on IgRT in patients with secondary immunodeficiency (SID) due to B-cell lymphoproliferative diseases are limited. Here, we examine the correlation between approved IgRT indications, treatment recommendations, and clinical practice in SID. Methods: An international online survey of 230 physicians responsible for the diagnosis of SID and the prescription of IgRT in patients with hematological malignancies was conducted. Results: Serum immunoglobulin was measured in 83% of patients with multiple myeloma, 76% with chronic lymphocytic leukemia, and 69% with non-Hodgkin lymphoma. Most physicians (85%) prescribed IgRT after ≥2 severe infections. In Italy, Germany, Spain, and the United States, immunoglobulin use was above average in patients with hypogammaglobulinemia, while in the UK considerably fewer patients received IgRT. The use of subcutaneous immunoglobulin was highest in France (34%) S U PP O RTI N G I N FO R M ATI O N Additional supporting information may be found online in the Supporting Information section at the end of the article. How to cite this article: Na I-K, Buckland M, Agostini C, et al. Current clinical practice and challenges in the management of secondary immunodeficiency in hematological malignancies. Eur J Haematol. 2019;102:447-456. https://doi.
| INTRODUC TI ON
Hypogammaglobulinemia is characterized by a decrease in functional or total serum immunoglobulin (Ig) levels and can lead to immunodeficiency associated with recurrent and severe infections. as well as the consequent increased survival rates in lymphoproliferative diseases have led to an increased diversity and incidence of SID in hematological malignancies. 3 In chronic lymphocytic leukemia (CLL), up to 85% of patients develop hypogammaglobulinemia and infections are the major cause of morbidity and mortality, contributing to 25%-50% of deaths. [4] [5] [6] [7] Similarly, life-threatening infections are a major cause of morbidity and mortality in multiple myeloma (MM), with 30% being fatal, and have increased since the introduction of novel therapies. [8] [9] [10] Treatment of immunodeficiency by immunoglobulin replacement therapy (IgRT) is well established in PID due to proven efficacy and safety. 11 In SID, despite being more prevalent than PID, clinical data on IgRT are limited. Evidence for the use of IgRT in CLL and MM is predominantly based on clinical trials performed 20-30 years ago, before modern immunosuppressive therapies were introduced. 10,12-14 A meta-analysis of randomized trials in patients with CLL and MM reported that prophylactic IgRT significantly reduced major and clinically documented infections, but did not improve survival. 15 Immunoglobulin replacement therapy may be administered intravenously (IV) or subcutaneously (SC). In PID, both routes of administration have been shown to be effective and safe. European consensus proposals recommend that patients with PID should be given the choice between IVIG and SCIG. 16, 17 In SID, the safety and efficacy of SCIG has been demonstrated in case series in patients with lymphoproliferative diseases and hypogammaglobulinemia. 12, 18 SCIG might have several advantages over IVIG to some patients. SCIG does not require venous access and allows more flexible and convenient self-administration at home than IVIG. 12 SCIG has been associated with an improvement in perceived health-related quality of life. 12, 19 Additionally, pharmacokinetics may be preferable, as SCIG treatment leads to higher and more stable IgG trough levels, providing patients with a more consistent protection against infections. 1, 20 The use of SCIG varies greatly between countries. For example, in Scandinavia, SCIG is used in 80%-90% of PID patients, while in Spain, France, and Italy IVIG is used predominantly. 21 In the United States and Europe, national recommendations regarding the use of IgRT in hypogammaglobulinemia associated with hematological malignancies extend to conditions beyond those included in the marketing authorizations, although the recommendations are often not based on strong evidence and vary widely. 11 In addition to promoting off-label use, differences in current recommendations highlight open questions regarding the selection of patients who might benefit from IgRT, such as Ig and Ig subclass serum levels, testing specific antibody responses, test immunization, and infection history. In a 2014 European consensus statement, the determination of serum Ig concentrations and the levels of specific serum antibody titers in response to vaccination was agreed as a useful approach for patient selection in SID, although the need for more research was acknowledged. 17 and lowest in Spain (19%). Immunologists measured specific antibody responses, performed test immunization, implemented IgRT, and used subcutaneous immunoglobulin more frequently than physicians overall.
Conclusions:
The management of SID in hematological malignancies varied regionally.
Clinical practice did not reflect treatment guidelines, highlighting the need for robust clinical studies on IgRT in this population and harmonization between countries and disciplines. IgRT after a period of time, 6 months to a year, has been suggested by some experts. 7, 22 Agostini et al 11 recommended that treatment discontinuation may be considered in patients with a stable primary condition who have received IgRT for more than a year and who have not reported infectious episodes during this period. However, patients who continue to have no B-cells or memory B-cells, and those who lack IgA and IgM and with conditions such as CLL, where hypogammaglobulinemia is commonly progressive over time, are likely to experience increased number of severe infections due to immunodeficiency, once prophylaxis is stopped. 12 In view of these heterogeneous treatment guidelines for SID in patients with hematological malignancies, assessing current clinical practice is of great interest. We present an international online survey on the daily clinical practice of SID diagnosis and treatment in hematological malignancies. The aim of the survey was to document current treatment practices and challenges in SID across countries and to identify discrepancies between treatment indications, treatment recommendations, and daily practice as well as regional differences in SID treatment. Other HSCT, hematopoietic stem cell transplantation; Ig, immunoglobulin. 
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| RE SULTS
| Survey population
In total, 230 physicians from the United States (N = 50), Canada, the UK, France, Italy, Spain, and Germany (N = 30 each) participated in the survey (Table 1) measured Ig serum levels in all patients after two or more severe infections, 68% and 69% of physicians measured Ig before and after hematopoietic stem cell transplantation and 64% after first severe infection ( Table 2 ).
| Recurring infections
| Monitoring and diagnostic practice
The measurement of specific antibody responses varied across countries ( Table 2) . Over one-third of respondents (38%) did not measure specific antibody responses in general. Spanish, Italian, and USA physicians measured specific antibody responses more frequently than physicians overall, probably due to the higher proportion of immunologists in these countries included in the survey.
Specific antibody responses were mostly measured before and after vaccination (referred to as test immunization). 
| Choice of infection prophylaxis
Prophylactic IgRT in patients with hypogammaglobulinemia was mostly prescribed after two or more severe infections (85% of physicians) or after the first severe infection (65% of physicians; Figure 1 and Table S1 ). IgRT prescription practice was generally comparable across most countries, but there was some variation (Table S1 ). In Italy, Germany, Spain, and the United States, Ig use in patients with hypogammaglobulinemia was generally above average. The combined use of Ig and antibiotics was slightly more widespread in the United States compared with Europe. Concomitant use of Ig and antibiotics was particularly rare in the UK, where Ig use was much less pronounced and antibiotic use was much more prominent. In the UK, only 3% or less physicians used both antibiotics and Ig after insufficient vaccination response against pneumococcus, after any infection, and after lower respiratory tract infection. The combination of Ig and antibiotics was half as frequent in the UK after the first severe infection (17%) and after two or more severe infections (30%) compared with the average across all countries (36% and 60%, respectively).
| Treatment with IgRT by indication
The average proportion of patients reportedly treated with Ig alone and/ or in parallel with antibiotics was comparable across CLL (32%), MM (33%), NHL (25%), and other lymphoproliferative diseases (26%), with approximately one-quarter to one-third of patients being treated across each indication ( Figure 2 ). There were some regional differences in the frequency of IgRT across indications. 
Patients in
| Route of administration and dose
The reported use of SCIG was highest in France (34%) followed by the United States (30%), Italy (27%), and Germany (25%). Lowest SCIG use was reported in Spain (19%) preceded by the UK (21%) and
Canada (22%). The average initial monthly starting dose of IgG was 0.35 g/kg body weight (BW). Higher doses of 0.4-0.5 g/kg BW were prescribed by 70% of immunologists (n = 32). No substantial differences were observed between countries.
| Duration of treatment
Over 80% of physicians prescribed Ig regardless of the season.
The reported mean Ig treatment duration was comparable across countries and indications with 10-12 months, ranging from 1 to 60 months (Table S2 ). Physicians in Italy reported the shortest treatment durations across all indication with a mean of 7 months, probably due to tighter cost control in these countries. The main reasons reported for discontinuing Ig therapy were no infection for 12 months and adequate specific antibody response by 39% of physicians, followed by no infections for 6 months by 26% of physicians. IgG trough levels were reported as the main reason for discontinuing Ig therapy by 17% of all physicians but 37% of French physicians.
| Immunologist responses
Immunologists followed recommendations more closely than oncologists/hematologists overall. Only 6% of immunologists (n = 32) did not measure specific antibody responses compared to 38% of physicians. Over two-thirds of immunologists reported performing test immunizations whereas only one-third of physicians did ( Table 2) .
Immunologists prescribed Ig in more patients (CLL: 63%, MM: 54%, NHL: 47%, other: 27%), than physicians (CLL: 32%, MM: 33%, NHL: 25%, other: 26%), possibly because most patients were referred to the immunologists specifically for Ig treatment. Immunologists also used Ig more often than physicians before any infection occurred and when vaccination responses were insufficient. Immunologists used higher doses of IgG, with 70% using initial monthly doses of 0.4-0.5 g/kg BW compared with 45% of physicians across all countries. Immunologists also used SCIG more frequently than physicians (44% vs 25%).
| D ISCUSS I ON
Two recent publications reported data on the management of SID in patients with malignancies: the prospective, observational German SIGNS study, and a survey among British and Irish immunologists on the prescription practice of IgRT in SID. 23, 24 The present online survey of 230 physicians identifies a discrepancy between approved indications, published recommendations, and daily routine in the treatment of SID in patients with hematological malignancies on an international level.
Approved indications for Ig products differ between countries.
In Canada, IVIG and SCIG concentrates are generally indicated for use in SID. 25, 26 In the EU, as of 2019 the approved indications for IVIG in SID have been widened from patients with CLL, MM and patients after allogeneic hematopoietic stem cell transplantation, 28, 29 to patients who suffer from severe or recurrent bacterial infections, ineffective antibiotic treatment and either proven specific antibody failure (failure to mount at least a two-fold rise in IgG antibody titer to pneumococcal polysaccharide and polypeptide antigen vaccines) or serum IgG level of <4 g/L. 30 In the USA, only a single Ig concentrate is approved for use in CLL. 31 No other products are approved for other hematological malignancies, and SCIG is only approved for PID. (Figure 2 ). In addition, 30% of USA physicians prescribed SCIG, despite it not being approved in SID. These data indicate harmonization of clinical practice, despite regional indication differences and the lack of harmonized treatment guidelines.
Although Ig levels were generally monitored in NHL and other lymphoproliferative diseases, a significant proportion of this subpopulation was reported to develop severe or recurring infections.
In addition, in Canada, France, Germany, and the UK, the reported sessing and monitoring specific antibody responses. 11, 34 In this online survey, over one-third of respondents did not measure specific antibody responses, while immunologists were much more likely to measure specific antibody responses. Contrary to recommendations to systematically perform test immunizations in patients with SID, only one-third (33%) of surveyed physicians did so on average. 11 Over two-thirds (68%) of immunologists performed test immunizations, which is in line with the data reported for British and Irish immunologists. 24 These data indicate that immunologists follow the recommendations more closely. However, there is no evidence that increased monitoring results in improved outcomes (or less infection or decreased mortality) since supporting clinical data are lacking.
In contrast to German recommendations to initiate IgRT after at least three severe bacterial infections per year, 33 German physicians frequently prescribed prophylactic IgRT after the first severe infection (67%), after lower respiratory infection (50%), after any infection occurs (47%), and even before any infection occurs (33%).
These data are in line with findings of the German observational prospective SIGNS study, which reported that most of the patients newly treated with IgRT did not fulfill the German recommendations regarding the frequency of severe infections. 23 This divergence between recommendations and clinical practice points to the need for clinical studies to evaluate the use of IgRT at an early stage in a patient's primary disease, as suggested previously. 11, 34 The high reported use of prophylactic antibiotics in the UK is consistent with reports of 85% of British and Irish immunologists prescribing prophylactic antibiotics in all, or most, of their patients before starting Ig therapy. 24 These observations might be explained by the inclusion of recurrent or severe bacterial infections despite continuous oral antibiotic therapy for 3 months as selection criteria for IgRT in the British clinical guidelines for Ig use. 35 The reported use of SCIG was unexpectedly high, ranging from 19% to 34%. These numbers seem an overestimation of the actual use in these countries. For example, 6.5% of patients received SCIG in the recent German SIGNS study. 23 Regional differences may be a consequence of national reimbursement policies. Notably, data were collected from physicians rather than from patient records. In addition, the proportion of patients with hypogammaglobulinemia and/ or severe infections as separate or concomitant events was not analyzed. Furthermore, it might be of interest to further stratify the reported data by diseases grouped as "other lymphoproliferative diseases." This study did not capture data on chemotherapeutic medication used to treat the different hematological malignancies. In future studies, it would be interesting to assess how different B-cell targeting therapies across the investigated disease entities impact on the incidence and management of SID.
| CON CLUS IONS
The survey revealed discrepancies among daily practice, clinical practice, guideline recommendations, and currently approved indications. This underlines the medical need for more evidence from robust clinical trials, especially in hematological malignancies other than CLL and MM, in order to optimize the risk stratification of patients and to guide the identification of those patients likely to benefit from IgRT. 
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